ClinicalTrials.gg
CompletedNCT04816721RSVPEDsUpdated Jul 28, 2025Results posted

A Study to Evaluate EDP 938 Regimens in Children With RSV

A Phase 2 interventional study of EDP-938 and Placebo in Respiratory Syncytial Virus (RSV), sponsored by Enanta Pharmaceuticals, Inc. Completed at 78 sites in 15 countries. Open to participants aged 28 Days to 36 Months. Per ClinicalTrials.gov, last updated 2025-07-28.

Sponsored by Enanta Pharmaceuticals, Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
99
Allocation
Randomized
Ages
28 Days to 36 Months
Sex
All
01

Study summary

A 2-part study to evaluate the safety, pharmacokinetics and efficacy of EDP-938 in children with RSV infection.

Read the detailed description

This is a randomized, double-blind, dose ranging, placebo-controlled study in respiratory syncytial virus (RSV) among hospitalized and non-hospitalized children aged from 28 days to 36 months, assessing the safety, tolerability, pharmacokinetics, clinical outcome and antiviral activity of a 5 day treatment with EDP-938.

02

Conditions studied

  • Respiratory Syncytial Virus (RSV)

Keywords

  • Respiratory Syncytial Virus, RSV, Pediatric study
03

In context

Lead sponsor

Enanta Pharmaceuticals, Inc is the lead sponsor of 46 studies on the registry; 3 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
28 Days to 36 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female who is either ≥6 months to ≤36 months (for Age Group 1) or ≥28 days to \<6 months (for Age Group 2), defined at the time of randomization. Subjects in Age Group 2 must have been born ≥29 weeks of gestation to be eligible.
  • Subjects diagnosed with RSV infection
  • Subjects with signs of an acute respiratory illness with onset ≤7 days for Part 1 and ≤5 days for Part 2 before the time of signing the ICF
  • In the Investigator's opinion, the subject's caregiver understands and is able to comply with protocol requirements, instructions, and protocol-stated restrictions, and the subject is likely to complete the study as planned

Exclusion criteria

Exclusion Criteria:

  • Use of or anticipated need for invasive mechanical ventilation, cardiopulmonary bypass, hemodialysis, or extracorporeal membrane oxygenation; or subjects who are not expected to survive the current illness
  • Underlying immune deficiency, (e.g., from confirmed infection or use of an medication except immunoglobulin A deficiency)
  • Receipt of (within 12 months before Screening) or on a waiting list for a bone marrow, stem cell, or solid organ transplant, or who received radiation or chemotherapy (within 12 months before screening)
  • Receiving chronic oxygen therapy at home before admission
  • Subjects whose mother received an RSV vaccination while pregnant with the subject if they were born at term (≥37 weeks of gestation) and are less than 12 months of age
  • In Part 2, subjects dosed with an investigational or approved medication that is intended to prevent or treat RSV infection within the following times before the first dose of study drug: ribavirin 35 days; palivizumab 100 days; nirsevimab 350 days; other RSV-specific monoclonal antibody 5 half-lives of the specific antibody; RSV vaccines 12 months.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
99 participants (actual)

Study arms

  • Experimental
    EDP-938

    EDP-938, oral suspension, once daily for 5 days

    Drug: EDP-938

  • Placebo comparator
    Placebo

    Matching placebo, orally, once daily for 5 days

    Drug: Placebo

Interventions

  • Oral suspension

  • DrugPlacebo

    Placebo oral suspension to match EDP-938

06

What researchers measure

Primary outcomes

  1. Part 1: Concentrations of EDP-938 in Plasma

    Plasma concentrations of EDP-938 were assessed at the designated time points.

    Time frame: 3 hours post-dose on Day 1 and pre-dose on Day 2 (hospitalized participants only), Day 3, and Day 5

  2. Part 1: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)

    TEAEs were defined as any event, side effect, or untoward medical occurrence in a participant enrolled in a clinical study whether or not it was considered to have a causal relationship to the study drug and first occurred or worsened during the post-baseline phase compared to baseline. Clinically significant changes from baseline in vital signs and clinical laboratory results were reported as TEAEs.

    Time frame: Day 1 to Day 28

  3. Part 2: Model-Adjusted Daily Change From Baseline in Respiratory Syncytial Virus (RSV) Shedding in Nasal Swab Samples

    Daily change from baseline in RSV shedding was defined as the daily change from baseline in RSV ribonucleic acid (RNA) viral load and was measured using reverse transcription-quantitative polymerase chain reaction (RT-qPCR) from nasal swabs. The model included treatment group (EDP-938, placebo) and Day (3, 5, 9, and 14) as fixed effect, associated baseline, and treatment group by Day interaction term as factors. An unstructured covariance matrix was imposed. The Satterthwaite approximation is used to estimate the denominator degrees of freedom.

    Time frame: Baseline and pre-dose on Days 3, 5, 9, and 14

  4. Pooled Population: Model-Adjusted Daily Change From Baseline in RSV Shedding in Nasal Swab Samples

    Daily change from baseline in RSV shedding was defined as the daily change from baseline in RSV RNA viral load and was measured using RT-qPCR from nasal swabs. The model included treatment group (EDP-938, placebo) and Day (3, 5, 9, and 14) as fixed effect, associated baseline, and treatment group by Day interaction term as factors. An unstructured covariance matrix was imposed.The Satterthwaite approximation is used to estimate the denominator degrees of freedom.

    Time frame: Baseline and pre-dose on Days 3, 5, 9, and 14

Secondary outcomes

  1. Part 1 and Part 2: Area Under the Curve (AUC) for RSV RNA Viral Load

    The RSV RNA viral load was measured using RT-qPCR from nasal swabs. The AUC was calculated using the trapezoid rule. The AUC was calculated based on all available assessments collected on Days 1, 3, 5, 9 and 14 and the actual date/time of each assessment was used for the calculation.

    Time frame: Pre-dose on Day 1 through pre-dose on Days 3, 5, 9 and 14

  2. Pooled Population: AUC of Change From Baseline in RSV RNA Viral Load

    The RSV RNA viral load was measured using RT-qPCR from nasal swabs. The AUC was calculated using the trapezoid rule. The AUC was calculated based on all available assessments collected on Days 1, 3, 5, 9 and 14 and the actual date/time of each assessment was used for the calculation. The model included treatment group (EDP-938, placebo) and Day (3, 5, 9, and 14) as fixed effect, associated baseline, and treatment group by day interaction term as factors. An unstructured covariance matrix was imposed. The Satterthwaite approximation was used to estimate the denominator degrees of freedom.

    Time frame: Baseline (Pre-dose on Day 1) through pre-dose on Days 3, 5, 9 and 14

  3. Part 1: Daily Change From Baseline in RSV Shedding in Nasal Swab Samples

    Daily change from baseline in RSV shedding in nasal swab samples was defined as the absolute daily change from baseline in RSV RNA viral load and measured using RT-qPCR from nasal swabs.

    Time frame: Baseline to pre-dose on Days 3, 5, 9, and Day 14

  4. Part 1 and Part 2: Percentage of Participants With RSV RNA Viral Load Below the Limit of Detection (LOD)

    The RSV RNA viral load was measured using RT-qPCR from nasal swabs.

    Time frame: Pre-dose on Days 3, 5, 9 and 14

  5. Pooled Population: Percentage of Participants With RSV RNA Viral Load Below the LOD

    The RSV RNA viral load was measured using RT-qPCR from nasal swabs.

    Time frame: Pre-dose on Days 3, 5, 9 and 14

  6. Part 1 and Part 2: Time to RSV RNA Viral Load Being Undetectable

    Time to RSV RNA viral load being undetectable was calculated as: first date of RSV RNA viral load target not detected (TND) after which no further samples had detectable RSV RNA viral load - date of first dose.

    Time frame: Day 1 to Day 28

  7. Pooled Population: Time to RSV RNA Viral Load Being Undetectable

    Time to RSV RNA viral load being undetectable was calculated as: first date of RSV RNA viral load TND after which no further samples had detectable RSV RNA viral load - date of first dose.

    Time frame: Day 1 to Day 28

  8. Part 2: Number of Participants Who Experienced a TEAE

    TEAEs were defined as any event, side effect, or untoward medical occurrence in a participant enrolled in a clinical study whether or not it was considered to have a causal relationship to the study drug and first occurred or worsened during the post-baseline phase compared to baseline. Clinically significant changes from baseline in vital signs and clinical laboratory results were reported as TEAEs.

    Time frame: Day 1 to Day 28

  9. Pooled Population: Number of Participants Who Experienced a TEAE

    TEAEs were defined as any event, side effect, or untoward medical occurrence in a participant enrolled in a clinical study whether or not it was considered to have a causal relationship to the study drug and first occurred or worsened during the post-baseline phase compared to baseline. Clinically significant changes from baseline in vital signs and clinical laboratory results were reported as TEAEs.

    Time frame: Day 1 to Day 28

  10. Part 2: Concentrations of EDP-938 in Plasma

    Plasma concentrations of EDP-938 were assessed at the designated time points.

    Time frame: 3 hours post-dose on Day 1 and pre-dose on Day 2 (hospitalized participants only), Day 3, and Day 5

  11. Pooled Population: Concentrations of EDP-938 in Plasma

    Plasma concentrations of EDP-938 were assessed at the designated time points.

    Time frame: 3 hours post-dose on Day 1 and pre-dose on Day 2 (hospitalized participants only), Day 3, and Day 5

  12. Part 2: Time to First Hospital Discharge for Hospitalized Participants

    Time to first discharge for participants who were hospitalized at randomization was calculated as: date/time of first discharge - date/time of first dose with conversion to days. For participants with continuous hospitalization, the last date of discharge from the continuous hospitalization was used.

    Time frame: Day 1 to Day 28

  13. Pooled Population: Time to First Hospital Discharge for Hospitalized Participants

    Time to first discharge for participants who were hospitalized at randomization was calculated as: date/time of first discharge - date/time of first dose with conversion to days. For participants with continuous hospitalization, the last date of discharge from the continuous hospitalization was used.

    Time frame: Day 1 to Day 28

  14. Part 2: Time to Use of Oxygen for Hospitalized Participants Who Were Not Receiving Oxygen at the Time They Received the First Dose of Study Drug

    For participants were were hospitalized at randomization, time to use of oxygen for hospitalization participants who were not receiving oxygen at the time they received the first dose of study drug was calculated as: first date/time of receiving oxygen - date/time of first dose of study drug with conversion to days.

    Time frame: Day 1 to Day 28

  15. Pooled Population: Time to Use of Oxygen for Hospitalized Participants Who Were Not Receiving Oxygen at the Time They Received the First Dose of Study Drug

    For participants were were hospitalized at randomization, time to use of oxygen for hospitalization participants who were not receiving oxygen at the time they received the first dose of study drug was calculated as: first date/time of receiving oxygen - date/time of first dose of study drug with conversion to days.

    Time frame: Day 1 to Day 28

  16. Part 2: Percentage of Hospitalized Participants Who Required Oxygen Supplementation or Had an Increased Oxygen Requirement After the First Dose of Study Drug

    The numerator in the percentage calculation was defined by the number of participants who developed a new requirement for oxygen supplementation or new increase in oxygen requirements after the first dose of study drug, based on the response of "yes" to the "Is this an increase of oxygen supplementation compared to previous use?" question on the Oxygen Supplementation case report form (CRF). The 95% confidence interval was reported using the Clopper Pearson confidence interval methods.

    Time frame: Day 1 to Day 28

  17. Pooled Population: Percentage of Hospitalized Participants Who Required Oxygen Supplementation or Had an Increased Oxygen Requirement After the First Dose of Study Drug

    The numerator in the percentage calculation was defined by the number of participants who developed a new requirement for oxygen supplementation or new increase in oxygen requirements after the first dose of study drug, based on the response of "yes" to the "Is this an increase of oxygen supplementation compared to previous use?" question on the Oxygen Supplementation CRF. The 95% confidence interval was reported using the Clopper Pearson confidence interval methods.

    Time frame: Day 1 to Day 28

  18. Part 2: Time to Mechanical Ventilation for Hospitalized Participants

    Time to mechanical ventilation for participants who were hospitalized at randomization was calculated as: first date/time of mechanical ventilation - date/time of first dose of study drug with conversion to days. Participants who were on mechanical ventilation before their first dose of study drug were excluded from the analysis.

    Time frame: Day 1 to Day 28

  19. Pooled Population: Time to Mechanical Ventilation for Hospitalized Participants

    Time to mechanical ventilation for participants who were hospitalized at randomization was calculated as: first date/time of mechanical ventilation - date/time of first dose of study drug with conversion to days. Participants who were on mechanical ventilation before their first dose of study drug were excluded from the analysis.

    Time frame: Day 1 to Day 28

  20. Part 2: Percentage of Hospitalized Participants Who Required Mechanical Ventilation

    The numerator in the percentage calculation was defined by the number of participants who developed a new requirement for mechanical ventilation after the first dose of study drug. Participants on mechanical ventilation prior to the first dose of study drug were excluded from analysis. The 95% confidence interval was reported using the Clopper Pearson confidence interval methods.

    Time frame: Day 1 to Day 28

  21. Pooled Population: Percentage of Hospitalized Participants Who Required Mechanical Ventilation

    The numerator in the percentage calculation was defined by the number of participants who developed a new requirement for mechanical ventilation after the first dose of study drug. Participants on mechanical ventilation prior to the first dose of study drug were excluded from analysis. The 95% confidence interval was reported using the Clopper Pearson confidence interval methods.

    Time frame: Day 1 to Day 28

  22. Part 2: Percentage of Hospitalized Participants Who Died During the Study

    The percentage of hospitalized participants who died during the study included deaths from any cause. The 95% confidence interval was reported using the Clopper Pearson confidence interval methods.

    Time frame: Day 1 to Day 28

  23. Pooled Population: Percentage of Hospitalized Participants Who Died During the Study

    The percentage of hospitalized participants who died during the study included deaths from any cause. The 95% confidence interval was reported using the Clopper Pearson confidence interval methods.

    Time frame: Day 1 to Day 28

  24. Part 2: Time to Hospitalization for Initial Outpatients Who Were Subsequently Hospitalized

    Time to hospitalization for initial outpatients who are not hospitalized at randomization but subsequently hospitalized was calculated as: first date/time of hospitalization - date/time of first dose with conversion to days.

    Time frame: Day 1 to Day 28

  25. Pooled Population: Time to Hospitalization for Initial Outpatients Who Were Subsequently Hospitalized

    Time to hospitalization for initial outpatients who are not hospitalized at randomization but subsequently hospitalized was calculated as: first date/time of hospitalization - date/time of first dose with conversion to days.

    Time frame: Day 1 to Day 28

  26. Part 2: Percentage of Outpatients Who Were Subsequently Hospitalized or Died

    Participants who were hospitalized at randomization were excluded from the analysis. The 95% confidence interval was reported using the Clopper Pearson confidence interval methods.

    Time frame: Day 1 to Day 28

  27. Pooled Population: Percentage of Outpatients Who Were Subsequently Hospitalized or Died

    Participants who were hospitalized at randomization were excluded from the analysis. The 95% confidence interval was reported using the Clopper Pearson confidence interval methods.

    Time frame: Day 1 to Day 28

  28. Part 2: Time to Resolution of Symptoms for Outpatients Who Were Not Hospitalized

    Resolution of symptoms was defined as the first of 2 consecutive timepoints where each of the seven symptoms assessed by the Parent/Caregiver Respiratory Syncytial Virus (RSV) Foundation (ReSVinet) score was 0 (not present) or 1 (mild). Time to resolution of symptoms for outpatients who were not hospitalized was calculated as: first date/time of resolution of symptoms - date/time of first dose with conversion to days. Participants who did not achieve resolution and had not been followed through the Day 14 visit or completed the Day 14 questionnaire were censored at Day 14. During the study, the parent(s)/caregiver(s) assessed the severity of RSV-related signs and symptoms. The ReSVinet assessed 7 symptoms, with each symptom being rated from 0 (not present) to 3 (severe), apart from fever which was scored from 0-2. The full range was 0 to 20 with higher scores representing more severe disease.

    Time frame: Day 1 to Day 14

  29. Pooled Population: Time to Resolution of Symptoms for Outpatients Who Were Not Hospitalized

    Resolution of symptoms was defined as the first of 2 consecutive timepoints where each of the seven symptoms assessed by the Parent/Caregiver ReSVinet score was 0 (not present) or 1 (mild). Time to resolution of symptoms for outpatients who were not hospitalized was calculated as: first date/time of resolution of symptoms - date/time of first dose with conversion to days. Participants who did not achieve resolution and had not been followed through the Day 14 visit or completed the Day 14 questionnaire were censored at Day 14. During the study, the parent(s)/caregiver(s) assessed the severity of RSV-related signs and symptoms. The ReSVinet assessed 7 symptoms, with each symptom being rated from 0 (not present) to 3 (severe), apart from fever which was scored from 0-2. The full range was 0 to 20 with higher scores representing more severe disease.

    Time frame: Day 1 to Day 14

07

Results

Posted Jul 8, 2025

Participant flow

A total of 99 participants were enrolled at 78 sites across 15 countries between April 2022 and August 2024.

Participant flow — Overall Study
MilestonePart 1, Group 1: EDP-938Part 1, Group 2: EDP-938Part 1, Group 1: PlaceboPart 1, Group 2: PlaceboPart 2, Group 1: EDP-938Part 2, Group 2: EDP-938Part 2, Group 1: PlaceboPart 2, Group 2: Placebo
Started2214116201664
Treated with 5 mg/kg edp-93814130081500
Treated with 7.5 mg/kg edp-938900011000
Treated with placebo001160064
Completed2212114191564
Not completed02021100
Withdrew: Withdrawal by subject02011000
Withdrew: Miscellaneous00000100
Withdrew: Lost to follow-up00010000

Outcome measures

PrimaryPart 1: Concentrations of EDP-938 in Plasma

Plasma concentrations of EDP-938 were assessed at the designated time points.

Time frame:
3 hours post-dose on Day 1 and pre-dose on Day 2 (hospitalized participants only), Day 3, and Day 5
Reported as:
Mean · ng/mL
Part 1: Concentrations of EDP-938 in Plasma
ng/mLPart 1: EDP-938 5mg/kg (≥ 28 Days to < 3 Months)Part 1: EDP-938 5mg/kg (≥ 3 Months to < 6 Months)Part 1: EDP-938 5mg/kg (≥ 6 Months to < 12 Months)Part 1: EDP-938 5mg/kg (≥ 12 Months to ≤ 36 Months)Part 1: EDP-938 7.5 mg/kg (≥ 12 Months to ≤ 36 Months)
Day 11132.222 ± 397.42891989.500 ± 1331.56461819.286 ± 809.95081420.000 ± 604.81401428.250 ± 817.4801
Day 2368.400 ± 149.8741399.250 ± 423.9515502.350 ± 379.6487249.675 ± 294.5416238.900 ± 239.0287
Day 3448.000 ± 229.1026—346.000 ± 54.744997.533 ± 64.9043116.250 ± 43.4871
Day 5528.563 ± 284.6010201.750 ± 98.6623431.429 ± 637.5664252.043 ± 329.2155180.622 ± 158.3268
PrimaryPart 1: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)

TEAEs were defined as any event, side effect, or untoward medical occurrence in a participant enrolled in a clinical study whether or not it was considered to have a causal relationship to the study drug and first occurred or worsened during the post-baseline phase compared to baseline. Clinically significant changes from baseline in vital signs and clinical laboratory results were reported as TEAEs.

Time frame:
Day 1 to Day 28
Reported as:
Count of participants · Participants
Part 1: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)
ParticipantsPart 1: EDP-938Part 1: Placebo
Part 1: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)149
PrimaryPart 2: Model-Adjusted Daily Change From Baseline in Respiratory Syncytial Virus (RSV) Shedding in Nasal Swab Samples

Daily change from baseline in RSV shedding was defined as the daily change from baseline in RSV ribonucleic acid (RNA) viral load and was measured using reverse transcription-quantitative polymerase chain reaction (RT-qPCR) from nasal swabs. The model included treatment group (EDP-938, placebo) and Day (3, 5, 9, and 14) as fixed effect, associated baseline, and treatment group by Day interaction term as factors. An unstructured covariance matrix was imposed. The Satterthwaite approximation is used to estimate the denominator degrees of freedom.

Time frame:
Baseline and pre-dose on Days 3, 5, 9, and 14
Reported as:
Least squares mean · log10 copies/mL
Part 2: Model-Adjusted Daily Change From Baseline in Respiratory Syncytial Virus (RSV) Shedding in Nasal Swab Samples
log10 copies/mLPart 2: EDP-938Part 2: Placebo
Day 3-1.33 ± 0.297-0.37 ± 0.533
Day 5-3.04 ± 0.354-1.62 ± 0.627
Day 9-3.65 ± 0.381-3.22 ± 0.680
Day 14-4.87 ± 0.388-5.71 ± 0.677
Statistical analysis
  • Part 2: EDP-938 vs Part 2: Placebo · Mixed-effect Model of Repeated Measures · p = 0.1249 · Least squares mean difference: -0.96 · 95% CI -2.21 to 0.28
  • Part 2: EDP-938 vs Part 2: Placebo · Mixed-effect Model of Repeated Measures · p = 0.0580 · Least squares mean difference: -1.41 · 95% CI -2.88 to 0.05
  • Part 2: EDP-938 vs Part 2: Placebo · Mixed-effect Model of Repeated Measures · p = 0.5877 · Least squares mean difference: -0.43 · 95% CI -2.02 to 1.16
  • Part 2: EDP-938 vs Part 2: Placebo · Mixed-effect Model of Repeated Measures · p = 0.2932 · Least squares mean difference: 0.84 · 95% CI -0.76 to 2.43
PrimaryPooled Population: Model-Adjusted Daily Change From Baseline in RSV Shedding in Nasal Swab Samples

Daily change from baseline in RSV shedding was defined as the daily change from baseline in RSV RNA viral load and was measured using RT-qPCR from nasal swabs. The model included treatment group (EDP-938, placebo) and Day (3, 5, 9, and 14) as fixed effect, associated baseline, and treatment group by Day interaction term as factors. An unstructured covariance matrix was imposed.The Satterthwaite approximation is used to estimate the denominator degrees of freedom.

Time frame:
Baseline and pre-dose on Days 3, 5, 9, and 14
Reported as:
Least squares mean · log10 copies/mL
Pooled Population: Model-Adjusted Daily Change From Baseline in RSV Shedding in Nasal Swab Samples
log10 copies/mLCombined EDP-938Combined Placebo
Day 3-1.53 ± 0.192-1.36 ± 0.331
Day 5-2.95 ± 0.230-2.62 ± 0.392
Day 9-4.57 ± 0.275-3.87 ± 0.475
Day 14-5.01 ± 0.278-5.35 ± 0.462
Statistical analysis
  • Combined EDP-938 vs Combined Placebo · Mixed-effect Model of Repeated Measures · p = 0.6574 · Least squares mean difference: -0.17 · 95% CI -0.93 to 0.59
  • Combined EDP-938 vs Combined Placebo · Mixed-effect Model of Repeated Measures · p = 0.4728 · Least squares mean difference: -0.33 · 95% CI -1.23 to 0.58
  • Combined EDP-938 vs Combined Placebo · Mixed-effect Model of Repeated Measures · p = 0.2058 · Least squares mean difference: -0.70 · 95% CI -1.79 to 0.39
  • Combined EDP-938 vs Combined Placebo · Mixed-effect Model of Repeated Measures · p = 0.5391 · Least squares mean difference: 0.33 · 95% CI -0.74 to 1.41
SecondaryPart 1 and Part 2: Area Under the Curve (AUC) for RSV RNA Viral Load

The RSV RNA viral load was measured using RT-qPCR from nasal swabs. The AUC was calculated using the trapezoid rule. The AUC was calculated based on all available assessments collected on Days 1, 3, 5, 9 and 14 and the actual date/time of each assessment was used for the calculation.

Time frame:
Pre-dose on Day 1 through pre-dose on Days 3, 5, 9 and 14
Reported as:
Mean · log10 copies/mL*Days
Part 1 and Part 2: Area Under the Curve (AUC) for RSV RNA Viral Load
log10 copies/mL*DaysPart 1: EDP-938Part 1: PlaceboPart 2: EDP-938Part 2: Placebo
Day 1 through Day 317.80 ± 4.52217.26 ± 4.69117.15 ± 4.66316.91 ± 3.266
Day 1 through Day 525.54 ± 8.30124.55 ± 8.45724.76 ± 7.91426.22 ± 7.069
Day 1 through Day 936.03 ± 16.22935.20 ± 17.15637.00 ± 13.65240.39 ± 13.371
Day 1 through Day 1442.85 ± 24.99044.16 ± 25.05645.49 ± 21.10942.17 ± 19.864
SecondaryPooled Population: AUC of Change From Baseline in RSV RNA Viral Load

The RSV RNA viral load was measured using RT-qPCR from nasal swabs. The AUC was calculated using the trapezoid rule. The AUC was calculated based on all available assessments collected on Days 1, 3, 5, 9 and 14 and the actual date/time of each assessment was used for the calculation. The model included treatment group (EDP-938, placebo) and Day (3, 5, 9, and 14) as fixed effect, associated baseline, and treatment group by day interaction term as factors. An unstructured covariance matrix was imposed. The Satterthwaite approximation was used to estimate the denominator degrees of freedom.

Time frame:
Baseline (Pre-dose on Day 1) through pre-dose on Days 3, 5, 9 and 14
Reported as:
Least squares mean · log10 copies/mL*Days
Pooled Population: AUC of Change From Baseline in RSV RNA Viral Load
log10 copies/mL*DaysCombined EDP-938Combined Placebo
Day 1 through Day 3-1.53 ± 0.192-1.36 ± 0.331
Day 1 through Day 5-6.00 ± 0.540-5.33 ± 0.930
Day 1 through Day 9-21.04 ± 1.319-18.32 ± 2.272
Day 1 through Day 14-45.00 ± 2.105-41.36 ± 3.619
Statistical analysis
  • Combined EDP-938 vs Combined Placebo · Mixed-effect Model of Repeated Measures · p = 0.6574 · Least squares mean difference: -0.17 · 95% CI -0.93 to 0.59
  • Combined EDP-938 vs Combined Placebo · Mixed-effect Model of Repeated Measures · p = 0.5359 · Least squares mean difference: -0.67 · 95% CI -2.81 to 1.47
  • Combined EDP-938 vs Combined Placebo · Mixed-effect Model of Repeated Measures · p = 0.3029 · Least squares mean difference: -2.73 · 95% CI -7.95 to 2.50
  • Combined EDP-938 vs Combined Placebo · Mixed-effect Model of Repeated Measures · p = 0.3871 · Least squares mean difference: -3.64 · 95% CI -11.98 to 4.69
SecondaryPart 1: Daily Change From Baseline in RSV Shedding in Nasal Swab Samples

Daily change from baseline in RSV shedding in nasal swab samples was defined as the absolute daily change from baseline in RSV RNA viral load and measured using RT-qPCR from nasal swabs.

Time frame:
Baseline to pre-dose on Days 3, 5, 9, and Day 14
Reported as:
Mean · log10 copies/mL
Part 1: Daily Change From Baseline in RSV Shedding in Nasal Swab Samples
log10 copies/mLPart 1: EDP-938Part 1: Placebo
Day 3-1.68 ± 1.239-2.17 ± 1.948
Day 5-2.91 ± 1.634-3.44 ± 1.585
Day 9-5.34 ± 2.338-4.41 ± 1.897
Day 14-5.11 ± 2.378-5.15 ± 2.118
SecondaryPart 1 and Part 2: Percentage of Participants With RSV RNA Viral Load Below the Limit of Detection (LOD)

The RSV RNA viral load was measured using RT-qPCR from nasal swabs.

Time frame:
Pre-dose on Days 3, 5, 9 and 14
Reported as:
Number · percentage of participants
Part 1 and Part 2: Percentage of Participants With RSV RNA Viral Load Below the Limit of Detection (LOD)
percentage of participantsPart 1: EDP-938Part 1: PlaceboPart 2: EDP-938Part 2: Placebo
Day 30 (0.00 to 10.28)8.3 (0.21 to 38.48)3.6 (0.09 to 18.35)0 (0.00 to 33.63)
Day 512.1 (3.40 to 28.20)16.7 (2.09 to 48.41)22.2 (8.62 to 42.26)0 (0.00 to 33.63)
Day 962.5 (43.69 to 78.90)36.4 (10.93 to 69.21)28.0 (12.07 to 49.39)25.0 (3.19 to 65.09)
Day 1461.3 (42.19 to 78.15)58.3 (27.67 to 84.83)63.0 (42.37 to 80.60)88.9 (51.75 to 99.72)
SecondaryPooled Population: Percentage of Participants With RSV RNA Viral Load Below the LOD

The RSV RNA viral load was measured using RT-qPCR from nasal swabs.

Time frame:
Pre-dose on Days 3, 5, 9 and 14
Reported as:
Number · percentage of participants
Pooled Population: Percentage of Participants With RSV RNA Viral Load Below the LOD
percentage of participantsCombined EDP-938Combined Placebo
Day 31.6 (0.04 to 8.66)4.8 (0.12 to 23.82)
Day 516.7 (8.29 to 28.52)9.5 (1.17 to 30.38)
Day 947.4 (33.98 to 61.03)31.6 (12.58 to 56.55)
Day 1462.1 (48.37 to 74.49)71.4 (47.82 to 88.72)
SecondaryPart 1 and Part 2: Time to RSV RNA Viral Load Being Undetectable

Time to RSV RNA viral load being undetectable was calculated as: first date of RSV RNA viral load target not detected (TND) after which no further samples had detectable RSV RNA viral load - date of first dose.

Time frame:
Day 1 to Day 28
Reported as:
Mean · days
Part 1 and Part 2: Time to RSV RNA Viral Load Being Undetectable
daysPart 1: EDP-938Part 1: PlaceboPart 2: EDP-938Part 2: Placebo
Part 1 and Part 2: Time to RSV RNA Viral Load Being Undetectable10.59 ± 3.66112.33 ± 3.01812.46 ± 3.23512.19 ± 3.040
SecondaryPooled Population: Time to RSV RNA Viral Load Being Undetectable

Time to RSV RNA viral load being undetectable was calculated as: first date of RSV RNA viral load TND after which no further samples had detectable RSV RNA viral load - date of first dose.

Time frame:
Day 1 to Day 28
Reported as:
Mean · days
Pooled Population: Time to RSV RNA Viral Load Being Undetectable
daysCombined EDP-938Combined Placebo
Pooled Population: Time to RSV RNA Viral Load Being Undetectable11.45 ± 3.57012.27 ± 2.958
SecondaryPart 2: Number of Participants Who Experienced a TEAE

TEAEs were defined as any event, side effect, or untoward medical occurrence in a participant enrolled in a clinical study whether or not it was considered to have a causal relationship to the study drug and first occurred or worsened during the post-baseline phase compared to baseline. Clinically significant changes from baseline in vital signs and clinical laboratory results were reported as TEAEs.

Time frame:
Day 1 to Day 28
Reported as:
Count of participants · Participants
Part 2: Number of Participants Who Experienced a TEAE
ParticipantsPart 2: EDP-938Part 2: Placebo
Part 2: Number of Participants Who Experienced a TEAE144
SecondaryPooled Population: Number of Participants Who Experienced a TEAE

TEAEs were defined as any event, side effect, or untoward medical occurrence in a participant enrolled in a clinical study whether or not it was considered to have a causal relationship to the study drug and first occurred or worsened during the post-baseline phase compared to baseline. Clinically significant changes from baseline in vital signs and clinical laboratory results were reported as TEAEs.

Time frame:
Day 1 to Day 28
Reported as:
Count of participants · Participants
Pooled Population: Number of Participants Who Experienced a TEAE
ParticipantsCombined EDP-938Combined Placebo
Pooled Population: Number of Participants Who Experienced a TEAE2813
SecondaryPart 2: Concentrations of EDP-938 in Plasma

Plasma concentrations of EDP-938 were assessed at the designated time points.

Time frame:
3 hours post-dose on Day 1 and pre-dose on Day 2 (hospitalized participants only), Day 3, and Day 5
Reported as:
Mean · ng/mL
Part 2: Concentrations of EDP-938 in Plasma
ng/mLPart 2: EDP-938 5mg/kg (≥ 28 Days to < 3 Months)Part 2: EDP-938 5mg/kg (≥ 3 Months to < 6 Months)Part 2: EDP-938 5mg/kg (≥ 6 Months to < 12 Months)Part 2: EDP-938 7.5 mg/kg (≥ 12 Months to ≤ 36 Months)
Day 11116.286 ± 217.99831169.903 ± 802.07441551.429 ± 363.84191368.111 ± 469.7815
Day 2585.400 ± 119.6089273.500 ± 150.4616140.783 ± 73.3099200.700 ± 134.3896
Day 3194.000 ± NA926.000 ± 57.9828112.000 ± NA115.967 ± 84.9347
Day 5516.333 ± 247.6697519.714 ± 436.813069.110 ± 40.4604153.450 ± 102.4372
SecondaryPooled Population: Concentrations of EDP-938 in Plasma

Plasma concentrations of EDP-938 were assessed at the designated time points.

Time frame:
3 hours post-dose on Day 1 and pre-dose on Day 2 (hospitalized participants only), Day 3, and Day 5
Reported as:
Mean · ng/mL
Pooled Population: Concentrations of EDP-938 in Plasma
ng/mLCombined EDP-938 5mg/kg (≥ 28 Days to < 3 Months)Combined EDP-938 5mg/kg (≥ 3 Months to < 6 Months)Combined EDP-938 5mg/kg (≥ 6 Months to < 12 Months)Combined EDP-938 5mg/kg (≥ 12 Months to ≤ 36 Months)Combined EDP-938 7.5 mg/kg (≥ 12 Months to ≤ 36 Months)
Day 11125.250 ± 321.42781443.102 ± 1027.51971685.357 ± 619.02671420.000 ± 604.81401396.412 ± 635.3537
Day 2458.817 ± 173.0322323.800 ± 276.9576285.410 ± 293.0727249.675 ± 294.5416221.269 ± 191.0117
Day 3363.333 ± 218.5162926.000 ± 57.9828287.500 ± 125.247897.533 ± 64.9043116.080 ± 63.8730
Day 5522.918 ± 257.0945404.091 ± 378.3365250.269 ± 472.9799252.043 ± 329.2155167.835 ± 131.6054
SecondaryPart 2: Time to First Hospital Discharge for Hospitalized Participants

Time to first discharge for participants who were hospitalized at randomization was calculated as: date/time of first discharge - date/time of first dose with conversion to days. For participants with continuous hospitalization, the last date of discharge from the continuous hospitalization was used.

Time frame:
Day 1 to Day 28
Reported as:
Mean · days
Part 2: Time to First Hospital Discharge for Hospitalized Participants
daysPart 2: EDP-938Part 2: Placebo
Part 2: Time to First Hospital Discharge for Hospitalized Participants3.93 ± 1.8704.00 ± 3.367
SecondaryPooled Population: Time to First Hospital Discharge for Hospitalized Participants

Time to first discharge for participants who were hospitalized at randomization was calculated as: date/time of first discharge - date/time of first dose with conversion to days. For participants with continuous hospitalization, the last date of discharge from the continuous hospitalization was used.

Time frame:
Day 1 to Day 28
Reported as:
Mean · days
Pooled Population: Time to First Hospital Discharge for Hospitalized Participants
daysCombined EDP-938Combined Placebo
Pooled Population: Time to First Hospital Discharge for Hospitalized Participants3.71 ± 2.0063.57 ± 2.959
SecondaryPart 2: Time to Use of Oxygen for Hospitalized Participants Who Were Not Receiving Oxygen at the Time They Received the First Dose of Study Drug

For participants were were hospitalized at randomization, time to use of oxygen for hospitalization participants who were not receiving oxygen at the time they received the first dose of study drug was calculated as: first date/time of receiving oxygen - date/time of first dose of study drug with conversion to days.

Time frame:
Day 1 to Day 28

No measurements were reported for this outcome.

SecondaryPooled Population: Time to Use of Oxygen for Hospitalized Participants Who Were Not Receiving Oxygen at the Time They Received the First Dose of Study Drug

For participants were were hospitalized at randomization, time to use of oxygen for hospitalization participants who were not receiving oxygen at the time they received the first dose of study drug was calculated as: first date/time of receiving oxygen - date/time of first dose of study drug with conversion to days.

Time frame:
Day 1 to Day 28
Reported as:
Mean · days
Pooled Population: Time to Use of Oxygen for Hospitalized Participants Who Were Not Receiving Oxygen at the Time They Received the First Dose of Study Drug
daysCombined EDP-938Combined Placebo
Pooled Population: Time to Use of Oxygen for Hospitalized Participants Who Were Not Receiving Oxygen at the Time They Received the First Dose of Study Drug0.51 ± NA—
SecondaryPart 2: Percentage of Hospitalized Participants Who Required Oxygen Supplementation or Had an Increased Oxygen Requirement After the First Dose of Study Drug

The numerator in the percentage calculation was defined by the number of participants who developed a new requirement for oxygen supplementation or new increase in oxygen requirements after the first dose of study drug, based on the response of "yes" to the "Is this an increase of oxygen supplementation compared to previous use?" question on the Oxygen Supplementation case report form (CRF). The 95% confidence interval was reported using the Clopper Pearson confidence interval methods.

Time frame:
Day 1 to Day 28
Reported as:
Number · percentage of participants
Part 2: Percentage of Hospitalized Participants Who Required Oxygen Supplementation or Had an Increased Oxygen Requirement After the First Dose of Study Drug
percentage of participantsPart 2: EDP-938Part 2: Placebo
Part 2: Percentage of Hospitalized Participants Who Required Oxygen Supplementation or Had an Increased Oxygen Requirement After the First Dose of Study Drug24.1 (10.30 to 43.54)28.6 (3.67 to 70.96)
SecondaryPooled Population: Percentage of Hospitalized Participants Who Required Oxygen Supplementation or Had an Increased Oxygen Requirement After the First Dose of Study Drug

The numerator in the percentage calculation was defined by the number of participants who developed a new requirement for oxygen supplementation or new increase in oxygen requirements after the first dose of study drug, based on the response of "yes" to the "Is this an increase of oxygen supplementation compared to previous use?" question on the Oxygen Supplementation CRF. The 95% confidence interval was reported using the Clopper Pearson confidence interval methods.

Time frame:
Day 1 to Day 28
Reported as:
Number · percentage of participants
Pooled Population: Percentage of Hospitalized Participants Who Required Oxygen Supplementation or Had an Increased Oxygen Requirement After the First Dose of Study Drug
percentage of participantsCombined EDP-938Combined Placebo
Pooled Population: Percentage of Hospitalized Participants Who Required Oxygen Supplementation or Had an Increased Oxygen Requirement After the First Dose of Study Drug25.0 (14.39 to 38.37)19.0 (5.45 to 41.91)
SecondaryPart 2: Time to Mechanical Ventilation for Hospitalized Participants

Time to mechanical ventilation for participants who were hospitalized at randomization was calculated as: first date/time of mechanical ventilation - date/time of first dose of study drug with conversion to days. Participants who were on mechanical ventilation before their first dose of study drug were excluded from the analysis.

Time frame:
Day 1 to Day 28

No measurements were reported for this outcome.

SecondaryPooled Population: Time to Mechanical Ventilation for Hospitalized Participants

Time to mechanical ventilation for participants who were hospitalized at randomization was calculated as: first date/time of mechanical ventilation - date/time of first dose of study drug with conversion to days. Participants who were on mechanical ventilation before their first dose of study drug were excluded from the analysis.

Time frame:
Day 1 to Day 28

No measurements were reported for this outcome.

SecondaryPart 2: Percentage of Hospitalized Participants Who Required Mechanical Ventilation

The numerator in the percentage calculation was defined by the number of participants who developed a new requirement for mechanical ventilation after the first dose of study drug. Participants on mechanical ventilation prior to the first dose of study drug were excluded from analysis. The 95% confidence interval was reported using the Clopper Pearson confidence interval methods.

Time frame:
Day 1 to Day 28
Reported as:
Number · percentage of participants
Part 2: Percentage of Hospitalized Participants Who Required Mechanical Ventilation
percentage of participantsPart 2: EDP-938Part 2: Placebo
Part 2: Percentage of Hospitalized Participants Who Required Mechanical Ventilation0 (0.00 to 11.94)0 (0.00 to 40.96)
SecondaryPooled Population: Percentage of Hospitalized Participants Who Required Mechanical Ventilation

The numerator in the percentage calculation was defined by the number of participants who developed a new requirement for mechanical ventilation after the first dose of study drug. Participants on mechanical ventilation prior to the first dose of study drug were excluded from analysis. The 95% confidence interval was reported using the Clopper Pearson confidence interval methods.

Time frame:
Day 1 to Day 28
Reported as:
Number · percentage of participants
Pooled Population: Percentage of Hospitalized Participants Who Required Mechanical Ventilation
percentage of participantsCombined EDP-938Combined Placebo
Pooled Population: Percentage of Hospitalized Participants Who Required Mechanical Ventilation0 (0.00 to 6.38)0 (0.00 to 16.11)
SecondaryPart 2: Percentage of Hospitalized Participants Who Died During the Study

The percentage of hospitalized participants who died during the study included deaths from any cause. The 95% confidence interval was reported using the Clopper Pearson confidence interval methods.

Time frame:
Day 1 to Day 28
Reported as:
Number · percentage of participants
Part 2: Percentage of Hospitalized Participants Who Died During the Study
percentage of participantsPart 2: EDP-938Part 2: Placebo
Part 2: Percentage of Hospitalized Participants Who Died During the Study0 (0.00 to 11.94)0 (0.00 to 40.96)
SecondaryPooled Population: Percentage of Hospitalized Participants Who Died During the Study

The percentage of hospitalized participants who died during the study included deaths from any cause. The 95% confidence interval was reported using the Clopper Pearson confidence interval methods.

Time frame:
Day 1 to Day 28
Reported as:
Number · percentage of participants
Pooled Population: Percentage of Hospitalized Participants Who Died During the Study
percentage of participantsCombined EDP-938Combined Placebo
Pooled Population: Percentage of Hospitalized Participants Who Died During the Study0 (0.00 to 6.38)0 (0.00 to 16.11)
SecondaryPart 2: Time to Hospitalization for Initial Outpatients Who Were Subsequently Hospitalized

Time to hospitalization for initial outpatients who are not hospitalized at randomization but subsequently hospitalized was calculated as: first date/time of hospitalization - date/time of first dose with conversion to days.

Time frame:
Day 1 to Day 28

No measurements were reported for this outcome.

SecondaryPooled Population: Time to Hospitalization for Initial Outpatients Who Were Subsequently Hospitalized

Time to hospitalization for initial outpatients who are not hospitalized at randomization but subsequently hospitalized was calculated as: first date/time of hospitalization - date/time of first dose with conversion to days.

Time frame:
Day 1 to Day 28

No measurements were reported for this outcome.

SecondaryPart 2: Percentage of Outpatients Who Were Subsequently Hospitalized or Died

Participants who were hospitalized at randomization were excluded from the analysis. The 95% confidence interval was reported using the Clopper Pearson confidence interval methods.

Time frame:
Day 1 to Day 28
Reported as:
Number · percentage of participants
Part 2: Percentage of Outpatients Who Were Subsequently Hospitalized or Died
percentage of participantsPart 2: EDP-938Part 2: Placebo
Part 2: Percentage of Outpatients Who Were Subsequently Hospitalized or Died0 (0.00 to 52.18)0 (0.00 to 70.76)
SecondaryPooled Population: Percentage of Outpatients Who Were Subsequently Hospitalized or Died

Participants who were hospitalized at randomization were excluded from the analysis. The 95% confidence interval was reported using the Clopper Pearson confidence interval methods.

Time frame:
Day 1 to Day 28
Reported as:
Number · percentage of participants
Pooled Population: Percentage of Outpatients Who Were Subsequently Hospitalized or Died
percentage of participantsCombined EDP-938Combined Placebo
Pooled Population: Percentage of Outpatients Who Were Subsequently Hospitalized or Died0 (0.00 to 24.71)0 (0.00 to 45.93)
SecondaryPart 2: Time to Resolution of Symptoms for Outpatients Who Were Not Hospitalized

Resolution of symptoms was defined as the first of 2 consecutive timepoints where each of the seven symptoms assessed by the Parent/Caregiver Respiratory Syncytial Virus (RSV) Foundation (ReSVinet) score was 0 (not present) or 1 (mild). Time to resolution of symptoms for outpatients who were not hospitalized was calculated as: first date/time of resolution of symptoms - date/time of first dose with conversion to days. Participants who did not achieve resolution and had not been followed through the Day 14 visit or completed the Day 14 questionnaire were censored at Day 14. During the study, the parent(s)/caregiver(s) assessed the severity of RSV-related signs and symptoms. The ReSVinet assessed 7 symptoms, with each symptom being rated from 0 (not present) to 3 (severe), apart from fever which was scored from 0-2. The full range was 0 to 20 with higher scores representing more severe disease.

Time frame:
Day 1 to Day 14
Reported as:
Mean · days
Part 2: Time to Resolution of Symptoms for Outpatients Who Were Not Hospitalized
daysPart 2: EDP-938Part 2: Placebo
Part 2: Time to Resolution of Symptoms for Outpatients Who Were Not Hospitalized2.60 ± 1.6861.49 ± 0.702
SecondaryPooled Population: Time to Resolution of Symptoms for Outpatients Who Were Not Hospitalized

Resolution of symptoms was defined as the first of 2 consecutive timepoints where each of the seven symptoms assessed by the Parent/Caregiver ReSVinet score was 0 (not present) or 1 (mild). Time to resolution of symptoms for outpatients who were not hospitalized was calculated as: first date/time of resolution of symptoms - date/time of first dose with conversion to days. Participants who did not achieve resolution and had not been followed through the Day 14 visit or completed the Day 14 questionnaire were censored at Day 14. During the study, the parent(s)/caregiver(s) assessed the severity of RSV-related signs and symptoms. The ReSVinet assessed 7 symptoms, with each symptom being rated from 0 (not present) to 3 (severe), apart from fever which was scored from 0-2. The full range was 0 to 20 with higher scores representing more severe disease.

Time frame:
Day 1 to Day 14
Reported as:
Mean · days
Pooled Population: Time to Resolution of Symptoms for Outpatients Who Were Not Hospitalized
daysCombined EDP-938Combined Placebo
Pooled Population: Time to Resolution of Symptoms for Outpatients Who Were Not Hospitalized2.42 ± 1.1634.20 ± 5.552

Adverse events

Collected over Up to Day 28. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: EDP-9380/36 (0%)0/36 (0%)7/36 (19.4%)
Part 1: Placebo0/16 (0%)2/16 (12.5%)7/16 (43.8%)
Part 2: EDP-9380/34 (0%)1/34 (2.9%)9/34 (26.5%)
Part 2: Placebo0/10 (0%)0/10 (0%)4/10 (40%)
Most frequent serious events
Most frequent serious events
EventPart 1: EDP-938Part 1: PlaceboPart 2: EDP-938Part 2: Placebo
Pleural effusionRespiratory, thoracic and mediastinal disorders0/361/160/340/10
BronchiolitisInfections and infestations0/361/160/340/10
PneumoniaInfections and infestations0/360/161/340/10
Most frequent other events
Showing 10 of 16
Most frequent other events
EventPart 1: EDP-938Part 1: PlaceboPart 2: EDP-938Part 2: Placebo
DiarrhoeaGastrointestinal disorders4/361/163/340/10
Myocardial necrosis marker increasedInvestigations0/360/160/341/10
AnaemiaBlood and lymphatic system disorders0/360/160/341/10
PyrexiaGeneral disorders1/360/160/341/10
RashSkin and subcutaneous tissue disorders1/360/162/341/10
NasopharyngitisInfections and infestations0/361/161/341/10
VomitingGastrointestinal disorders0/361/160/340/10
Nasal congestionRespiratory, thoracic and mediastinal disorders0/361/161/340/10
Dermatitis diaperSkin and subcutaneous tissue disorders1/361/160/340/10
EczemaSkin and subcutaneous tissue disorders1/361/161/340/10

Baseline characteristics

Safety Population: Included all participants who received any dose (including partial doses) of any study drug. Participants have been reported according to the actual treatment received. One participant was randomized to 7.5 mg/kg EDP-938, but received 5 mg/kg in error and one participant was randomized to placebo, but received 7.5 mg/kg EDP-938 in error.

Age, Customized
Age, Customized(Participants)Part 1, Group 1: EDP-938Part 1, Group 2: EDP-938Part 1, Group 1: PlaceboPart 1, Group 2: PlaceboPart 2, Group 1: EDP-938Part 2, Group 2: EDP-938Part 2, Group 1: PlaceboPart 2, Group 2: PlaceboTotal
≥ 28 days to < 3 months0904070222
≥ 3 months to < 6 months0402080216
≥ 6 months to < 12 months7040803022
≥ 12 months to ≤ 36 months160601103036
Sex: Female, Male
Sex: Female, Male(Participants)Part 1, Group 1: EDP-938Part 1, Group 2: EDP-938Part 1, Group 1: PlaceboPart 1, Group 2: PlaceboPart 2, Group 1: EDP-938Part 2, Group 2: EDP-938Part 2, Group 1: PlaceboPart 2, Group 2: PlaceboTotal
Female125351175149
Male11871881347
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1, Group 1: EDP-938Part 1, Group 2: EDP-938Part 1, Group 1: PlaceboPart 1, Group 2: PlaceboPart 2, Group 1: EDP-938Part 2, Group 2: EDP-938Part 2, Group 1: PlaceboPart 2, Group 2: PlaceboTotal
Hispanic or Latino12332663338
Not Hispanic or Latino1110741293157
Unknown or Not Reported000010001
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1, Group 1: EDP-938Part 1, Group 2: EDP-938Part 1, Group 1: PlaceboPart 1, Group 2: PlaceboPart 2, Group 1: EDP-938Part 2, Group 2: EDP-938Part 2, Group 1: PlaceboPart 2, Group 2: PlaceboTotal
Asian220013019
Black or African American3052320015
White18113212104262
Other001120206
Not Reported001100013
Unknown000010001
Hospitalization Status on Day 1
Hospitalization Status on Day 1(Participants)Part 1, Group 1: EDP-938Part 1, Group 2: EDP-938Part 1, Group 1: PlaceboPart 1, Group 2: PlaceboPart 2, Group 1: EDP-938Part 2, Group 2: EDP-938Part 2, Group 1: PlaceboPart 2, Group 2: PlaceboTotal
Yes16128517124377
No7121232119
08

Study locations

78 sites
  • Memorial Care Miller Children's and Women's Hospital
    Long Beach, California 90806, United States
  • University of California Los Angeles (UCLA)
    Los Angeles, California 90095, United States
  • University of California Davis
    Sacramento, California 95817, United States
  • Nemours Children's Hospital
    Orlando, Florida 32827, United States
  • South Tampa Center for Advanced Healthcare
    Tampa, Florida 33606, United States
  • Rexburg Pediatrics
    Rexburg, Idaho 83440, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Norton Children's Research Institute
    Louisville, Kentucky 40202, United States
  • MedPharmics - Lafayette
    Lafayette, Louisiana 70508, United States
  • LSU Health
    Shreveport, Louisiana 71101, United States
  • Willis-Knighton Health System
    Shreveport, Louisiana 71103, United States
  • Boston Children's Hospital - Division of Adolescent/Youth Adult Medicine
    Boston, Massachusetts 02115, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Le Bonheur Children's Hospital
    Memphis, Tennessee 38103, United States
  • Driscoll Children's Hospital
    Corpus Christi, Texas 78411, United States
  • Children's Health Specialty Center Dallas Campus
    Dallas, Texas 75207, United States
  • Clinica del Niño y la Familia
    Mar del Plata, Buenos Aires, Argentina
  • Hospital Interzonal Dr Jose Penna
    Bahía Blanca, Argentina
  • Clínica Privada del Sol
    Buenos Aires, C1425, Argentina
  • Instituto Medico Rio Cuarto
    Río Cuarto, Argentina
  • Clinica Central S.A
    Villa Regina, Argentina
  • Sydney Children's Hospital - Randwick
    Randwick, New South Wales 2031, Australia
  • The Children's Hospital at Westmead
    Westmead, New South Wales 2145, Australia
  • Gold Coast University Hospital
    Southport, Australia
  • Instituto Méderi de Pesquisa e Saúde
    Passo Fundo, Rio Grande do Sul 99010, Brazil
  • Hospital de Clínicas de Porto Alegre
    Porto Alegre, Rio Grande do Sul 90035, Brazil
  • Irmandade da Santa Casa de Misericórdia Hospital - Porto Alegre
    Porto Alegre, Rio Grande do Sul 90035, Brazil
  • Universidade Federal do Paraná - Hospital de Clínicas
    Curitiba, 80060-900, Brazil
  • Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto
    Ribeirão Preto, 14015-010, Brazil
  • Universitätsklinikum Gießen und Marburg - Gießen
    Marburg, Bundesland 35043, Germany
  • Universitätsklinikum Erlangen
    Erlangen, Germany
  • Asklepios Klinik Sankt Augustin
    Sankt Augustin, Germany
  • Soroka University Medical Center
    Beersheba, Israel
  • Rambam Health Care
    Haifa, 3109601, Israel
  • Carmel Medical Center
    Haifa, Israel
  • Hadassah University Hospital Mount Scopu
    Jerusalem, Israel
  • Schneider Children's Medical Center Of Israel
    Petah Tikva, 4920235, Israel
  • Panamerican Clinical Research Mexico - Guadalajara
    Guadalajara, Prados 44670, Mexico
  • Instituto Nacional de Pediatría
    Mexico City, 04530, Mexico
  • Hospital Infantil De Mexico Federico Gomez
    Mexico City, Mexico
  • Karla Adriana Espinosa Bautista
    Mexico City, Mexico
  • IESCI Clinical Research
    Monterrey, Mexico
  • PanAmerican Clinical Research
    Querétaro, Mexico
  • SMIQ S de R.L de C.V
    Querétaro, Mexico
  • Wellington Regional Hospital
    Newtown, Wellington Region, New Zealand
  • IN-VIVO Bydgoszcz
    Bydgoszcz, Poland
  • Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Łodzi
    Lodz, Poland
  • Spital Clinic de Urgenta Pentru Copii Brasov
    Brasov, Brașov County, Romania
  • Spitalul Clinic Judetean De Urgenta Târgu Mureș
    Târgu Mureş, Târgu Mureș, Romania
  • Institutul National pentru Sanatatea Mamei si Copilului "Alessandrescu-Rusescu"
    Bucharest, Romania
  • Life Westville Hospital
    Westville, Durban, South Africa
  • Rahima Moosa Mother and Child Hospital
    Johannesburg, South Africa
  • Wits Clinical Research
    Soweto, 2013, South Africa
  • Nowon Eulji Medical Center, Eulji University
    Seoul, 1830, South Korea
  • Kyung Hee University Hospital
    Seoul, 2447, South Korea
  • Inje University Sanggye Paik Hospital
    Seoul, South Korea
  • Hospital Germans Trias i Pujol
    Barcelona, Spain
  • Hospital Universitario Arnau de Vilanova
    Lleida, Spain
  • Hospital Clínico San Carlos
    Madrid, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, Spain
  • Hospital Universitario Fundación Jiménez Díaz
    Madrid, Spain
  • Hospital Universitario La Paz
    Madrid, Spain
  • Hospital Universitario Puerta de Hierro - Majadahonda
    Madrid, Spain
  • Hospital Universitario Quirónsalud Madrid
    Madrid, Spain
  • Hospital Universitario Severo Ochoa
    Madrid, Spain
  • Unidad de Ensayos Clínicos Pediátricos
    Madrid, Spain
  • Hospital Regional Universitario de Málaga
    Málaga, Spain
  • Hospital Clínico Universitario de Santiago
    Santiago de Compostela, Spain
  • Hospital Universitario Joan XXIII de Tarragona
    Tarragona, Spain
  • National Taiwan University Hospital
    Taipei City, Taipei 100229, Taiwan
  • Linkou Chang Gung Memorial Hospital, Chang Gung Medical Foundation
    Taoyuan City, Taoyuan 333, Taiwan
  • Hsinchu Mackay Memorial Hospital
    Hsinchu, Taiwan
  • Chang Gung Memorial Hospital - Kaohsiung Branch
    Kaohsiung City, Taiwan
  • Chung Shan Medical University Hospital
    Taichung, Taiwan
  • Taipei Mackay Memorial Hospital
    Taipei, Taiwan
  • Nottingham University Hospitals NHS Trust
    Nottingham, Nottinghamshire NG5 1PB, United Kingdom
  • St. George's University Hospitals NHS Foundation Trust
    London, SW17 0QT, United Kingdom
  • Sheffield Children's NHS Foundation Trust
    Sheffield, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2022 to primary completion in Aug 2024, 27 months.

Results were first posted in Jul 2025, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2021
First posted
Mar 25, 2021
StartActual
Apr 26, 2022
Primary completionActual
Aug 19, 2024
CompletionActual
Aug 19, 2024
Results first posted
Jul 8, 2025
Last update
Jul 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04816721
Responsible party
Sponsor
First posted
Mar 25, 2021
Start date
Apr 26, 2022
Primary completion
Aug 19, 2024
Completion
Aug 19, 2024
Results posted
Jul 8, 2025
Last update
Jul 28, 2025

Study contacts

Enanta Pharmaceuticals, Inc
study director · Enanta Pharmaceuticals, Inc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: EDP-938

Start the discussion